Hypo-Fractionated Palliative QUADSHOT Radiotherapy and Concurrent CDDP in Patients with LAHNSCC: Toxicities and Clinical Outcomes

Suman Bhasker, Swaroop Kumar Pandey(All India Institute of Medical Sciences), Raja Pramanik(Cancer Institute (WIA)), V. Ghosh(All India Institute of Medical Sciences), S.K. Samala(All India Institute of Medical Sciences), D.V.S. Praveen(All India Institute of Medical Sciences), Somali Sanyal(Karolinska Institutet), Anubhuti Sharma(All India Institute of Medical Sciences), Ahitagni Biswas(DR. B.R.A. Institute Rotary Cancer Hospital), J. Pattanaik(All India Institute of Medical Sciences), Rakesh Kumar(All India Institute of Medical Sciences), S. Mandal(Bose Institute), R A.V., M.S. Tanwar(All India Institute of Medical Sciences)
International Journal of Radiation Oncology*Biology*Physics
September 29, 2023
10.1016/j.ijrobp.2023.06.1893
Cited by 0

Related Papers

HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis
|Radiotherapy and Oncology|2022|42
Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis
|Practical Radiation Oncology|2018|32
Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial
|Trials|2020|29
Non‐immunological biomarkers for assessment of villous abnormalities in patients with celiac disease
|Journal of Gastroenterology and Hepatology|2019|28
Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORT Palliative Studies
|International Journal of Radiation Oncology*Biology*Physics|2023|22